Journal
DRUG DISCOVERY TODAY
Volume 23, Issue 2, Pages 366-374Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2017.10.018
Keywords
-
Categories
Funding
- Spanish Ministry of Economy and Competitiveness [BIO2014-56092-R]
- FEDER [BIO2014-56092-R, BIO-267]
- PIE [P12-CTS-1507, CVI-6585]
- Andalucian Government [BIO-267]
Ask authors/readers for more resources
Zebrafish, an amenable small teleost fish with a complex mammal-like circulatory system, is being increasingly used for drug screening and toxicity studies. It combines the biological complexity of in vivo models with a higher-throughput screening capability compared with other available animal models. Externally growing, transparent embryos, displaying well-defined blood and lymphatic vessels, allow the inexpensive, rapid, and automatable evaluation of drug candidates that are able to inhibit neovascularisation. Here, we briefly review zebrafish as a model for the screening of anti(lymph) angiogenic drugs, with emphasis on the advantages and limitations of the different zebrafish-based in vivo assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available